References
- A.K. Byrum, A. Vindigni, N. Mosammaparast, Defining and Modulating ‘BRCAness’, Trends Cell Biol. 2019; 29(9): 740-751.
- M.J. Khoury, W.G. Feero, D.A. Chambers, L.C. Brody, N. Aziz, R.C. Green, A. Janssens, M.F. Murray, L.L. Rodriguez, J.L. Rutter, S.D. Schully, D.M. Winn, G.A. Mensah, A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health, PLoS Med. 2018; 15(8): e1002631.
- J.J. Grzymski, G. Elhanan, J.A. Morales Rosado, E. Smith, K.A. Schlauch, R. Read, C. Rowan, N. Slotnick, S. Dabe, W.J. Metcalf, B. Lipp, H. Reed, L. Sharma, E. Levin, J. Kao, M. Rashkin, J. Bowes, K. Dunaway, A. Slonim, N. Washington, M. Ferber, A. Bolze, J.T. Lu, Population genetic screening efficiently identifies carriers of autosomal dominant diseases, Nat Med. 2020; 26(8): 1235-1239.
- K.J. Karczewski, L.C. Francioli, G. Tiao, B.B. Cummings, J. Alföldi, Q. Wang, R.L. Collins, K.M. Laricchia, A. Ganna, D.P. Birnbaum, L.D. Gauthier, H. Brand, M. Solomonson, N.A. Watts, D. Rhodes, M. Singer-Berk, E.M. England, E.G. Seaby, J.A. Kosmicki, R.K. Walters, K. Tashman, Y. Farjoun, E. Banks, T. Poterba, A. Wang, C. Seed, N. Whiffin, J.X. Chong, K.E. Samocha, E. Pierce-Hoffman, Z. Zappala, A.H. O’Donnell-Luria, E.V. Minikel, B. Weisburd, M. Lek, J.S. Ware, C. Vittal, I.M. Armean, L. Bergelson, K. Cibulskis, K.M. Connolly, M. Covarrubias, S. Donnelly, S. Ferriera, S. Gabriel, J. Gentry, N. Gupta, T. Jeandet, D. Kaplan, C. Llanwarne, R. Munshi, S. Novod, N. Petrillo, D. Roazen, V. Ruano-Rubio, A. Saltzman, M. Schleicher, J. Soto, K. Tibbetts, C. Tolonen, G. Wade, M.E. Talkowski, B.M. Neale, M.J. Daly, D.G. MacArthur, The mutational constraint spectrum quantified from variation in 141,456 humans, Nature. 2020; 581(7809): 434-443.
- S.T. Sherry, M.H. Ward, M. Kholodov, J. Baker, L. Phan, E.M. Smigielski, K. Sirotkin, dbSNP: the NCBI database of genetic variation, Nucleic Acids Res. 2001; 29(1): 308-11.
- M.J. Landrum, S. Chitipiralla, G.R. Brown, C. Chen, B. Gu, J. Hart, D. Hoffman, W. Jang, K. Kaur, C. Liu, V. Lyoshin, Z. Maddipatla, R. Maiti, J. Mitchell, N. O’Leary, G.R. Riley, W. Shi, G. Zhou, V. Schneider, D. Maglott, J.B. Holmes, B.L. Kattman, ClinVar: improvements to accessing data, Nucleic Acids Res. 2020; 48(D1): D835-d844
- P.D. Stenson, M. Mort, E.V. Ball, M. Chapman, K. Evans, L. Azevedo, M. Hayden, S. Heywood, D.S. Millar, A.D. Phillips, D.N. Cooper, The Human Gene Mutation Database (HGMD(®)): optimizing its use in a clinical diagnostic or research setting, Hum Genet. 2020; 139(10): 1197-1207.
- S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W.W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H.L. Rehm, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med. 2015; 17(5): 405-24.
- J. O’Shaughnessy, C. Brezden-Masley, M. Cazzaniga, T. Dalvi, G. Walker, J. Bennett, S. Ohsumi, Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study, Breast Cancer Res. 2020; 22(1): 114.
- K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, K.A. Phillips, T.M. Mooij, M.J. Roos-Blom, S. Jervis, F.E. van Leeuwen, R.L. Milne, N. Andrieu, D.E. Goldgar, M.B. Terry, M.A. Rookus, D.F. Easton, A.C. Antoniou, L. McGuffog, D.G. Evans, D. Barrowdale, D. Frost, J. Adlard, K.R. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, S. Ellis, C. Nogues, C. Lasset, D. Stoppa-Lyonnet, J.P. Fricker, L. Faivre, P. Berthet, M.J. Hooning, L.E. van der Kolk, C.M. Kets, M.A. Adank, E.M. John, W.K. Chung, I.L. Andrulis, M. Southey, M.B. Daly, S.S. Buys, A. Osorio, C. Engel, K. Kast, R.K. Schmutzler, T. Caldes, A. Jakubowska, J. Simard, M.L. Friedlander, S.A. McLachlan, E. Machackova, L. Foretova, Y.Y. Tan, C.F. Singer, E. Olah, A.M. Gerdes, B. Arver, H. Olsson, Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, Jama. 2017; 317(23): 2402-2416.
- M. Okano, T. Nomizu, K. Tachibana, M. Nagatsuka, M. Matsuzaki, N. Katagata, T. Ohtake, S. Yokoyama, M. Arai, S. Nakamura, The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database, J Hum Genet. 2021; 66(3): 307-314.
- S. Chen, G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol 2007; 25(11): 1329-33.
- V. Sunar, V. Korkmaz, V. Topcu, B. Cavdarli, Z. Arik, B. Ozdal, Y.E. Ustun, Frequency of germline BRCA 1/BRCA 2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer, Asia Pac J Clin Oncol. 2021.
- A.L. Siu, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med. 2016; 164(4): 279-96.
- D.P. Atchley, C.T. Albarracin, A. Lopez, V. Valero, C.I. Amos, A.M. Gonzalez-Angulo, G.N. Hortobagyi, B.K. Arun, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J Clin Oncol. 2008; 26(26): 4282-8.
- E. Lee, R. McKean-Cowdin, H. Ma, D.V. Spicer, D. Van Den Berg, L. Bernstein, G. Ursin, Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women, J Clin Oncol. 2011; 29(33): 4373-80.
- E.V. Høgdall, M. Ringsholt, C.K. Høgdall, I.J. Christensen, J.S. Johansen, S.K. Kjaer, J. Blaakaer, L. Ostenfeld-Møller, P.A. Price, L.H. Christensen, YKL-40 tissue expression and plasma levels in patients with ovarian cancer, BMC Cancer 9 2009; 8.
- C. Hu, E.C. Polley, S. Yadav, J. Lilyquist, H. Shimelis, J. Na, S.N. Hart, D.E. Goldgar, S. Shah, T. Pesaran, J.S. Dolinsky, H. LaDuca, F.J. Couch, The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort, J Natl Cancer Inst. 2020; 112(12): 1231-1241.
- E. Fountzilas, I. Konstantopoulou, A. Vagena, P. Apostolou, C. Papadimitriou, C. Christodoulou, D. Tryfonopoulos, K. Manousou, A. Delimitsou, M. Papamentzelopoulou, G. Fountzilas, D. Yannoukakos, F. Fostira, Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clin Breast Cancer.2020; 20(2): 152-59.
- Y. Laitman, T.M Friebel, D. Yannoukakos, F. Fostira, I. Konstantopoulou, G. Figlioli, B. Bonanni, S. Manoukian, M. Zuradelli, C. Tondini, B. Pasini, P. Peterlongo, D. Plaseska-Karanfilska, M. Jakimovska, K. Majidzadeh, S. Zarinfam, M.A Loizidou, A. Hadjisavvas, K. Michailidou, K. Kyriacou, D. M Behar, R. B Molho, P. Ganz, P. James, M.T Parsons, A. Sallam, O.I Olopade, A. Seth, G. Chenevix-Trench, G. Leslie, L. McGuffog, M.J Marafie, A. Megarbane, F. Al-Mulla, T.R Rebbeck, E. Friedman, The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum Mutat. 2019; 40(11): 1-23.
- T. Mitamura, M. Sekine, M. Arai, Y. Shibata, M. Kato, S. Yokoyama, H. Yamashita, H. Watari, I. Yabe, H. Nomura, T. Enomoto, S. Nakamura, The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study, World J Surg Oncol. 2021; 19(1): 36.
- M. Arts-de Jong, G.H. de Bock, C.J. van Asperen, M.J. Mourits, J.A. de Hullu, C.M. Kets, Germline BRCA 1/BRCA 2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review, Eur J Cancer. 2016; 61: 137-45.
- S.R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J.G. Klijn, H. Meijers-Heijboer, P. Radice, S. Pilotti, H. Nevanlinna, R. Butzow, H. Sobol, J. Jacquemier, D.S. Lyonet, S.L. Neuhausen, B. Weber, T. Wagner, R. Winqvist, Y.J. Bignon, F. Monti, F. Schmitt, G. Lenoir, S. Seitz, U. Hamman, P. Pharoah, G. Lane, B. Ponder, D.T. Bishop, D.F. Easton, Pathology of ovarian cancers in BRCA1 and BRCA2 carriers, Clin Cancer Res. 2004; 10(7): 2473-81.
- B.M. Norquist, M.I. Harrell, M.F. Brady, T. Walsh, M.K. Lee, S. Gulsuner, S.S. Bernards, S. Casadei, Q. Yi, R.A. Burger, J.K. Chan, S.A. Davidson, R.S. Mannel, P.A. DiSilvestro, H.A. Lankes, N.C. Ramirez, M.C. King, E.M. Swisher, M.J. Birrer, Inherited Mutations in Women With Ovarian Carcinoma, JAMA Oncol. 2016; 2(4): 482-90.
- K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, B.Y. Karlan, D. Lambrechts, E. Despierre, D. Barrowdale, L. McGuffog, S. Healey, D.F. Easton, O. Sinilnikova, J. Benítez, M.J. García, S. Neuhausen, M.H. Gail, P. Hartge, S. Peock, D. Frost, D.G. Evans, R. Eeles, A.K. Godwin, M.B. Daly, A. Kwong, E.S. Ma, C. Lázaro, I. Blanco, M. Montagna, E. D’Andrea, M.O. Nicoletto, S.E. Johnatty, S.K. Kjær, A. Jensen, E. Høgdall, E.L. Goode, B.L. Fridley, J.T. Loud, M.H. Greene, P.L. Mai, A. Chetrit, F. Lubin, G. Hirsh-Yechezkel, G. Glendon, I.L. Andrulis, A.E. Toland, L. Senter, M.E. Gore, C. Gourley, C.O. Michie, H. Song, J. Tyrer, A.S. Whittemore, V. McGuire, W. Sieh, U. Kristoffersson, H. Olsson, Å. Borg, D.A. Levine, L. Steele, M.S. Beattie, S. Chan, R.L. Nussbaum, K.B. Moysich, J. Gross, I. Cass, C. Walsh, A.J. Li, R. Leuchter, O. Gordon, M. Garcia-Closas, S.A. Gayther, S.J. Chanock, A.C. Antoniou, P.D. Pharoah, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, Jama. 2012; 307(4): 382-90.
- A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, S. Sadetzki, Effect of BRCA 1/ BRCA 2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer, J Clin Oncol. 2008; 26(1): 20-5.
- D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S.B. Kaye, M.E. Gore, “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations, J Clin Oncol. 2008; 26(34): 5530-6.
- D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, A.K. Sood, W. Zhang, Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer, Jama. 2011; 306(14): 1557-65.
- C.C. Pritchard, J. Mateo, M.F. Walsh, N. De Sarkar, W. Abida, H. Beltran, A. Garofalo, R. Gulati, S. Carreira, R. Eeles, O. Elemento, M.A. Rubin, D. Robinson, R. Lonigro, M. Hussain, A. Chinnaiyan, J. Vinson, J. Filipenko, L. Garraway, M.E. Taplin, S. AlDubayan, G.C. Han, M. Beightol, C. Morrissey, B. Nghiem, H.H. Cheng, B. Montgomery, T. Walsh, S. Casadei, M. Berger, L. Zhang, A. Zehir, J. Vijai, H.I. Scher, C. Sawyers, N. Schultz, P.W. Kantoff, D. Solit, M. Robson, E.M. Van Allen, K. Offit, J. de Bono, P.S. Nelson, Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer, N Engl J Med. 2016; 375(5): 443-53.
- E. Castro, C. Goh, D. Olmos, E. Saunders, D. Leongamornlert, M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, E. Sawyer, R. Wilkinson, A. Ardern-Jones, S. Ellis, D. Frost, S. Peock, D.G. Evans, M. Tischkowitz, T. Cole, R. Davidson, D. Eccles, C. Brewer, F. Douglas, M.E. Porteous, A. Donaldson, H. Dorkins, L. Izatt, J. Cook, S. Hodgson, M.J. Kennedy, L.E. Side, J. Eason, A. Murray, A.C. Antoniou, D.F. Easton, Z. Kote-Jarai, R. Eeles, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol. 2013; 31(14): 1748-57.
- R. Na, S.L. Zheng, M. Han, H. Yu, D. Jiang, S. Shah, C.M. Ewing, L. Zhang, K. Novakovic, J. Petkewicz, K. Gulukota, D.L. Helseth, Jr., M. Quinn, E. Humphries, K.E. Wiley, S.D. Isaacs, Y. Wu, X. Liu, N. Zhang, C.H. Wang, J. Khandekar, P.J. Hulick, D.H. Shevrin, K.A. Cooney, Z. Shen, A.W. Partin, H.B. Carter, M.A. Carducci, M.A. Eisenberger, S.R. Denmeade, M. McGuire, P.C. Walsh, B.T. Helfand, C.B. Brendler, Q. Ding, J. Xu, W.B. Isaacs, Germline Mutations in ATM and BRCA 1/BRCA 2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death, Eur Urol. 2017; 71(5): 740-747.
- E. Castro, N. Romero-Laorden, A. Del Pozo, R. Lozano, A. Medina, J. Puente, J.M. Piulats, D. Lorente, M.I. Saez, R. Morales-Barrera, E. Gonzalez-Billalabeitia, Y. Cendón, I. García-Carbonero, P. Borrega, M.J. Mendez Vidal, A. Montesa, P. Nombela, E. Fernández-Parra, A. Gonzalez Del Alba, J.C. Villa-Guzmán, K. Ibáñez, A. Rodriguez-Vida, L. Magraner-Pardo, B. Perez-Valderrama, E. Vallespín, E. Gallardo, S. Vazquez, C.C. Pritchard, P. Lapunzina, D. Olmos, PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer, J Clin Oncol. 2019; 37(6): 490-503.
- J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, D. Nava Rodrigues, D. Robinson, A. Omlin, N. Tunariu, G. Boysen, N. Porta, P. Flohr, A. Gillman, I. Figueiredo, C. Paulding, G. Seed, S. Jain, C. Ralph, A. Protheroe, S. Hussain, R. Jones, T. Elliott, U. McGovern, D. Bianchini, J. Goodall, Z. Zafeiriou, C.T. Williamson, R. Ferraldeschi, R. Riisnaes, B. Ebbs, G. Fowler, D. Roda, W. Yuan, Y.M. Wu, X. Cao, R. Brough, H. Pemberton, R. A’Hern, A. Swain, L.P. Kunju, R. Eeles, G. Attard, C.J. Lord, A. Ashworth, M.A. Rubin, K.E. Knudsen, F.Y. Feng, A.M. Chinnaiyan, E. Hall, J.S. de Bono, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med. 2015; 373(18): 1697-708.
- J. Mateo, N. Porta, D. Bianchini, U. McGovern, T. Elliott, R. Jones, I. Syndikus, C. Ralph, S. Jain, M. Varughese, O. Parikh, S. Crabb, A. Robinson, D. McLaren, A. Birtle, J. Tanguay, S. Miranda, I. Figueiredo, G. Seed, C. Bertan, P. Flohr, B. Ebbs, P. Rescigno, G. Fowler, A. Ferreira, R. Riisnaes, R. Pereira, A. Curcean, R. Chandler, M. Clarke, B. Gurel, M. Crespo, D. Nava Rodrigues, S. Sandhu, A. Espinasse, P. Chatfield, N. Tunariu, W. Yuan, E. Hall, S. Carreira, J.S. de Bono, Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol. 2020; 21(1): 162-174.
- J. de Bono, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K.N. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, J. Kang, J. Burgents, W. Wu, A. Kohlmann, C.A. Adelman, M. Hussain, Olaparib for Metastatic Castration-Resistant Prostate Cancer, N Engl J Med. 2020; 382(22): 2091-2102.
- D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, I.F. Tannock, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol. 2008; 26(2): 242-5.
- K.M. Murphy, K.A. Brune, C. Griffin, J.E. Sollenberger, G.M. Petersen, R. Bansal, R.H. Hruban, S.E. Kern, Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%, Cancer Res. 2002; 62(13): 3789-93.
- Cancer risks in BRCA2 mutation carriers, J Natl Cancer Inst. 1999; 91(15): 1310-6.